Loading...
XETRHPHA
Market cap105mUSD
Dec 23, Last price  
2.18EUR
1D
-3.96%
1Q
-6.44%
Jan 2017
1.87%
IPO
-95.92%
Name

Heidelberg Pharma AG

Chart & Performance

D1W1MN
XETR:HPHA chart
P/E
P/S
10.30
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
10.56%
Rev. gr., 5y
21.87%
Revenues
10m
-46.75%
00010,000,00009,877,29317,841,17113,317,0003,597,0002,284,0001,362,0001,900,0003,668,0007,309,0008,487,9381,749,82918,514,0009,858,912
Net income
-20m
L+3.27%
00-20,447,665-12,729,262-23,089,229-13,925,727-9,390,797-5,040,320-5,700,849-6,551,617-6,389,034-10,970,172-11,671,980-10,148,135-18,373,602-26,633,194-19,702,096-20,346,486
CFO
-34m
L+279.87%
-14,619,340-20,966,100-21,502,233-18,449,173-19,239,462-8,998,871-5,107,798-14,452,365-6,620,125-4,796,042-6,534,884-7,939,952-9,983,237-8,556,707-17,892,611-26,610,610-8,863,943-33,671,799
Earnings
Jun 20, 2025

Profile

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
IPO date
Nov 13, 2006
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
9,859
-46.75%
18,514
958.05%
Cost of revenue
36,576
37,042
Unusual Expense (Income)
NOPBT
(26,717)
(18,528)
NOPBT Margin
Operating Taxes
1,916
Tax Rate
NOPAT
(26,717)
(20,444)
Net income
(20,346)
3.27%
(19,702)
-26.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
59
79,912
BB yield
Debt
Debt current
5,761
15,880
Long-term debt
254
295
Deferred revenue
1,168
5,903
Other long-term liabilities
77
Net debt
(37,424)
(65,189)
Cash flow
Cash from operating activities
(33,672)
(8,864)
CAPEX
(960)
(613)
Cash from investing activities
5,848
(598)
Cash from financing activities
(10,053)
84,001
FCF
(26,817)
(20,497)
Balance
Cash
43,439
81,329
Long term investments
35
Excess cash
42,946
80,439
Stockholders' equity
(255,439)
(238,096)
Invested Capital
311,778
326,330
ROIC
ROCE
EV
Common stock shares outstanding
46,596
37,235
Price
Market cap
EV
EBITDA
(25,838)
(17,771)
EV/EBITDA
Interest
762
840
Interest/NOPBT